AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's presentation of its research platform Alzstatin, which was presented at the scientific conference CTAD in San Francisco, is now available in its entirety on the company's website.
The abstract, titled AC-0027875, a novel gamma-secretase modulator for the treatment of Alzheimer’s disease, was presented by Dr. Johan Sandin and includes new preclinical results with AC-0027875 which show the substance's potent effects on amyloid production, indicating that compounds in the Alzstatin®-platform are promising as a preventive and disease-modifying treatment for early Alzheimer's disease.
The presentation included results with AC-0027875, a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin, which exhibited potent effects on toxic Aβ42 production in cells and animals. Data showed reductions of over 50% in vivo with a rapid onset of effect and good duration. AC-0027875 also had good pharmacokinetic properties with high penetration across the blood-brain barrier resulting in high concentration of the substance in the target organ, the brain.
GSM’s represents a promising class of small molecular Aβ42-lowering anti-amyloidogenic substances for preventive or disease-modifying treatment of Alzheimer's disease. A GSM exhibits several key properties that distinguish it from antibody treatments, including that it can be taken in tablet form, easily crosses the blood-brain barrier and can be produced more cost-effectively.
“Aβ42 plays an important pathogenic role in Alzheimer's disease and accumulates in the brain many years before clear symptoms develop. A GSM such as AC-0027875 is particularly well suited for early, preventive treatment, and these new promising results show that the substance rapidly reaches the brain in relevant concentrations, greatly reducing levels of harmful Aβ42,” said Gunnar Nordvall, Project leader and Director of Medicinal Chemistry at AlzeCure Pharma.
"We see a great interest for Alzstatin in the field as it offers access to a potentially preventive, non-invasive oral therapy for patients, and these new data further strengthen the commercial opportunities for our research platform Alzstatin," said Martin Jönsson, CEO of AlzeCure Pharma.
The abstract is available om AlzeCure’s website (https://www.alzecurepharma.se/en/presentations-and-interviews/).
